Cyclophosphamide and Filgrastim Followed By SCT in Patients With Chronic or Accelerated Phase Myelogenous Leukemia
Status:
Terminated
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Giving colony-stimulating factors, such as G-CSF, and cyclophosphamide helps stem
cells move from the patient's bone marrow to the blood so they can be collected and stored.
Chemotherapy and radiation therapy is then given to prepare the bone marrow for the stem cell
transplant. The stem cells are returned to the patient to replace the blood-forming cells
that were destroyed by the chemotherapy and radiation therapy.
PURPOSE: This phase II trial is studying how well cyclophosphamide plus filgrastim followed
by stem cell transplant works in treating patients with chronic phase or accelerated phase
chronic myelogenous leukemia.